Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

[1]  Lu Lu,et al.  Identification of Human Single-Domain Antibodies against SARS-CoV-2 , 2020, Cell Host & Microbe.

[2]  Qiang Zhou,et al.  A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability , 2020, bioRxiv.

[3]  Fang Li,et al.  Cell entry mechanisms of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.

[4]  Xiangxi Wang,et al.  Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.

[5]  Daniel Wrapp,et al.  Site-specific glycan analysis of the SARS-CoV-2 spike , 2020, Science.

[6]  Y. Uno.  Camostat mesilate therapy for COVID-19 , 2020, Internal and Emergency Medicine.

[7]  S. Jois,et al.  The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections , 2020, bioRxiv.

[8]  T. Cardozo,et al.  SARS‐CoV‐2 viral spike G614 mutation exhibits higher case fatality rate , 2020, International journal of clinical practice.

[9]  T. Jodlowski,et al.  Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[10]  J. Zhao,et al.  Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor , 2020, Cellular & Molecular Immunology.

[11]  Majid Sharifi,et al.  A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin , 2020, Journal of biomolecular structure & dynamics.

[12]  Amalio Telenti,et al.  Structural and functional analysis of a potent sarbecovirus neutralizing antibody , 2020, bioRxiv.

[13]  K. Yuen,et al.  Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 , 2020, Cell.

[14]  Susan Daniel,et al.  Coronavirus membrane fusion mechanism offers a potential target for antiviral development , 2020, Antiviral Research.

[15]  Lu Lu,et al.  Fully human single-domain antibodies against SARS-CoV-2 , 2020, bioRxiv.

[16]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[17]  Yuxian He,et al.  Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity , 2020, Journal of Virology.

[18]  Yan Liu,et al.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.

[19]  Lei Liu,et al.  Potent human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, bioRxiv.

[20]  R. Tiwari,et al.  COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics , 2020, Human vaccines & immunotherapeutics.

[21]  Qi Zhao,et al.  Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 , 2020, International journal of biological sciences.

[22]  Zhenhua Zhang,et al.  The establishment of reference sequence for SARS‐CoV‐2 and variation analysis , 2020, Journal of medical virology.

[23]  Cynthia Liu,et al.  Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases , 2020, ACS central science.

[24]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.

[25]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[26]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[27]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[28]  Lun Song,et al.  Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV , 2020, Cellular & Molecular Immunology.

[29]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target , 2020, Intensive Care Medicine.

[30]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[31]  B. Robson,et al.  Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus , 2020, Computers in Biology and Medicine.

[32]  Andrea Marzi,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[33]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[34]  Z. Zhao,et al.  Structure analysis of the receptor binding of 2019-nCoV , 2020, Biochemical and Biophysical Research Communications.

[35]  Lu Lu,et al.  Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein , 2020, Cellular & Molecular Immunology.

[36]  B. Canard,et al.  The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade , 2020, Antiviral Research.

[37]  W. Liu,et al.  Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV , 2020, Chembiochem : a European journal of chemical biology.

[38]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[39]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[40]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[41]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[42]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[43]  G. Schiff,et al.  Connecting With Patients-The Missing Links. , 2020, JAMA.

[44]  Bo Zhong,et al.  RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak , 2020, Emerging microbes & infections.

[45]  Zhènglì Shí,et al.  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody , 2020, bioRxiv.

[46]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[47]  Alfonso J. Rodriguez-Morales,et al.  SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview , 2020 .

[48]  Leon N. Schulte,et al.  TMPRSS2 Is the Major Activating Protease of Influenza A Virus in Primary Human Airway Cells and Influenza B Virus in Human Type II Pneumocytes , 2019, Journal of Virology.

[49]  K. Shirato,et al.  Biochemical Analysis of Coronavirus Spike Glycoprotein Conformational Intermediates during Membrane Fusion , 2019, Journal of Virology.

[50]  Alexandra C Walls,et al.  Structural basis for human coronavirus attachment to sialic acid receptors , 2019, Nature Structural & Molecular Biology.

[51]  Lu Lu,et al.  A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike , 2019, Science Advances.

[52]  R. Kleemann,et al.  FURIN Inhibition Reduces Vascular Remodeling and Atherosclerotic Lesion Progression in Mice , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[53]  Song-Qiang Xie,et al.  Inhibition of PIKfyve using YM201636 suppresses the growth of liver cancer via the induction of autophagy. , 2018, Oncology reports.

[54]  Zhènglì Shí,et al.  Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.

[55]  Lu Lu,et al.  Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains , 2018, International journal of molecular sciences.

[56]  Hong Wei,et al.  Furin inhibitor D6R suppresses epithelial-mesenchymal transition in SW1990 and PaTu8988 cells via the Hippo-YAP signaling pathway. , 2017, Oncology letters.

[57]  Axel Wismüller,et al.  Alteration of brain network topology in HIV-associated neurocognitive disorder: A novel functional connectivity perspective , 2017, NeuroImage: Clinical.

[58]  G. Whittaker,et al.  Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells , 2017, Virology.

[59]  K. Yuen,et al.  A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses , 2017, Nature Communications.

[60]  R. Guha,et al.  The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection , 2017, PLoS neglected tropical diseases.

[61]  Haixia Zhou,et al.  Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding , 2016, Cell Research.

[62]  H. Feldmann,et al.  Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model , 2016, Virus Research.

[63]  B. Bosch,et al.  Coronavirus Spike Protein and Tropism Changes , 2016, Advances in Virus Research.

[64]  T. Pan,et al.  Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) , 2016, The Journal of Biological Chemistry.

[65]  H. Klenk,et al.  Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells. , 2015, Antiviral research.

[66]  G. Gao,et al.  Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond , 2015, Trends in Microbiology.

[67]  S. Harrison,et al.  Viral membrane fusion. , 2015, Virology.

[68]  Y. Sakurai,et al.  Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment , 2015, Science.

[69]  S. Perlman,et al.  Coronaviruses: An Overview of Their Replication and Pathogenesis , 2015, Methods in molecular biology.

[70]  Gary R. Whittaker,et al.  Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis , 2014, Virus Research.

[71]  M. Frieman,et al.  Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice , 2014, Vaccine.

[72]  O. Jahn,et al.  TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein , 2013, Journal of Virology.

[73]  M. Habjan,et al.  TMPRSS2 Activates the Human Coronavirus 229E for Cathepsin-Independent Host Cell Entry and Is Expressed in Viral Target Cells in the Respiratory Epithelium , 2013, Journal of Virology.

[74]  Hiroshi Kido,et al.  Role of host cellular proteases in the pathogenesis of influenza and influenza-induced multiple organ failure. , 2012, Biochimica et biophysica acta.

[75]  S. Opal,et al.  Proprotein convertases in health and disease. , 2011, The New England journal of medicine.

[76]  K. Yuen,et al.  Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity , 2007, Biochemical and Biophysical Research Communications.

[77]  W. Kisiel,et al.  The serpin proteinase inhibitor 8: An endogenous furin inhibitor released from human platelets , 2006, Thrombosis and Haemostasis.

[78]  B. Bosch,et al.  SARS-CoV, But not HCoV-NL63, Utilizes Cathepsins to Infect Cells: Viral Entry , 2006, Advances in experimental medicine and biology.

[79]  Edward N. Trifonov,et al.  The Triplet Code From First Principles , 2004, Journal of biomolecular structure & dynamics.

[80]  A. Debnath,et al.  Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors , 2004, The Lancet.

[81]  B. Bosch,et al.  The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex , 2003, Journal of Virology.

[82]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[83]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[84]  S. Harrison,et al.  Structural basis for membrane fusion by enveloped viruses. , 1999, Molecular membrane biology.

[85]  R. Webster,et al.  Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus , 1998, The Lancet.

[86]  C. Pringle,et al.  Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. , 1990, The Journal of general virology.